Driver, a high profile clinical trials matching service made a splash. It attracted investor Li Ka-shing, Hong Kong’s richest man who contributed 20 percent of the funding raised since the company’s formation in 2015. Other funding came from individual investors as well as from Nexus Venture Partners. Despite more than 30 cancer center partners and other marketing arrangements the venture shut down this week as the investors did not want to continue funding the company. TrialSite News covered Driver in September 2018: https://trialsitenews.com/driver-a-new-technology-platform-connects-cancer-patients-to-the-best-treatments-worldwide/ and at the time we were suspect as to the long-term viability of the venture based on our understanding of clinical trials and patient recruitment models.